Pharmacological treatment with Diacerein (cas 13739-02-1) combined with mechanical stimulation affects the expression of growth factors in human chondrocytes
-
Add time:09/29/2019 Source:sciencedirect.com
BackgroundOsteoarthritis (OA) as the main chronic joint disease arises from a disturbed balance between anabolic and catabolic processes leading to destructions of articular cartilage of the joints. While mechanical stress can be disastrous for the metabolism of chondrocytes, mechanical stimulation at the physiological level is known to improve cell function. The disease modifying OA drug (DMOAD) Diacerein (cas 13739-02-1) functions as a slowly-acting drug in OA by exhibiting anti-inflammatory, anti-catabolic, and pro-anabolic properties on cartilage. Combining these two treatment options revealed positive effects on OA-chondrocytes.
We also recommend Trading Suppliers and Manufacturers of Diacerein (cas 13739-02-1). Pls Click Website Link as below: cas 13739-02-1 suppliers
Prev:Formulation and optimization of niosomes for topical Diacerein (cas 13739-02-1) delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis
Next:Reaserch paperMechanistic studies on metabolic chiral inversion of 4-(4-methylphenyl)-2-methylthiomethyl-4-oxobutanoic acid (KE-748), an active metabolite of the new anti-rheumatic agent 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298), in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Formulation and optimization of niosomes for topical Diacerein (cas 13739-02-1) delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis09/28/2019
- Original articleDiacerein (cas 13739-02-1) orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial10/01/2019
- Original articleDiacerein (cas 13739-02-1) alleviates kidney injury through attenuating inflammation and oxidative stress in obese insulin-resistant rats09/27/2019
- Original ArticleValidated determination of Diacerein (cas 13739-02-1) and its active metabolite, rhein, by stability indicating constant pattern method as a novel manipulation of zero order spectra09/26/2019
- Diacerein (cas 13739-02-1) inhibits Estradiol-benzoate induced cervical hyperkeratosis in female rats09/25/2019
- Mechanical exposure and Diacerein (cas 13739-02-1) treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes09/24/2019
- Diacerein (cas 13739-02-1) protects against glycerol-induced acute kidney injury: Modulating oxidative stress, inflammation, apoptosis and necroptosis09/10/2019
- Novel spectrophotometric methods for the determination of Leflunomide and Diacerein (cas 13739-02-1) in binary mixtures09/09/2019
- Original articlePharmacokinetics and bioequivalence study of rhein as the main metabolite of Diacerein (cas 13739-02-1)09/08/2019